Core Viewpoint - Shanghai Dongzhou Asset Appraisal Co., Ltd. has responded to the inquiry letter regarding the asset purchase and fundraising by Shanghai Aopumai Biotechnology Co., Ltd., detailing the evaluation of the target company, Pengli Bio, with a final transaction price of 1,450.507 million yuan [1] Evaluation Methodology - The evaluation utilized both the income approach and market approach to assess the total equity value of the target company, with the income approach yielding a value of 1,452 million yuan and a value increase rate of 56.62%, while the market approach provided a value of 1,485 million yuan with a 60.18% increase rate [1][2] - The market approach involved comparing the target company with comparable companies based on various operational metrics, and the key parameters used in this evaluation were deemed reasonable [2] Income Approach Advantages - The income approach reflects the target company's future profitability by discounting expected cash flows, which is considered more reliable than the market approach due to the unique operational characteristics of each company and the volatility of market prices [3] - The target company has established a stable delivery system with over 1,800 disease animal models, indicating a solid operational foundation and growth potential [3] Industry Context - The recent valuation differs significantly from previous capital increases due to changes in the biopharmaceutical CRO industry, which saw inflated valuations in early 2022 but has since faced a slowdown in investment and increased competition [4] - The previous capital increase in March 2022 valued the company at 3.22 billion yuan, and the current evaluation reflects the industry's downward trend [4] Revenue and Cost Projections - Revenue forecasts for various segments are considered cautious yet achievable, with the pharmacodynamics evaluation business expected to grow faster than the industry average due to the company's competitive advantages and strategic initiatives [5] - Cost and expense forecasts are comprehensive, with reasonable assumptions regarding gross margins and operating expenses compared to industry peers [5][6] Capital Expenditure and Working Capital - Future capital expenditures are projected to be reasonable, including both renewal and expansion investments, while working capital calculations account for changes in business operations [7] - The discount rate used in the evaluation is within the range of comparable cases, reflecting the specific risks faced by the target company [7] Asset Treatment and Performance Coverage - Surplus assets are treated as working capital, aligning with industry practices, and the classification of non-operating assets is deemed reasonable [8] - The target company achieved 45.38% of its projected revenue and 45.80% of its projected net profit for the first half of 2025, indicating a strong likelihood of meeting future performance targets [9] - The projected compound annual growth rate for net profit from 2025 to 2029 is 20.29%, slightly above the industry average, supporting the reasonableness of the evaluation [9]

经中国证券监督管理委员会《关于同意上海奥浦迈生物科技股份有限公司首 次公开发行股票注册的批复》（证监许可〔2022〕1232 号）核准，上海奥浦迈生 物科技股份有限公司（以下简称"奥浦迈"、"上市公司"、"公司"或"发行人"） 首次公开发行人民币普通股（A 股）2,049.5082 万股，每股面值人民币 1 元，发 行价格为每股人民币 80.20 元，募集资金总额为人民币 1,643,705,576.40 元，扣 除发行费用后实际募集资金净额为人民币 1,510,944,779.75 元。本次发行证券已 于 2022 年 9 月 2 日在上海证券交易所上市。国泰海通证券股份有限公司（以下 简称"保荐机构"或"国泰海通"）担任其持续督导保荐机构，持续督导期间为 2022 年 9 月 2 日至 2025 年 12 月 31 日。 国泰海通证券股份有限公司 关于上海奥浦迈生物科技股份有限公司 2025 年半年度持续督导跟踪报告 | 保荐机构名称：国泰海通证券股份有限公司 | 被保荐公司简称：奥浦迈 | | --- | --- | | 保荐代表人姓名：靳宇辰、王冰 | 被保荐公司代码：688293.SH | 重大事项 ...

Group 1 - The core viewpoint of the news is that Aopumai's stock price has decreased by 5.05%, currently trading at 50.37 CNY per share, with a total market capitalization of 5.719 billion CNY [1] - Aopumai Biotechnology Co., Ltd. was established on November 27, 2013, and went public on September 2, 2022. The company specializes in cell culture products and services, with revenue composition being 87.34% from products, 12.53% from services, and 0.13% from other sources [1] - The trading volume for Aopumai was 64.8416 million CNY, with a turnover rate of 1.10% [1] Group 2 - Among Aopumai's top ten circulating shareholders, a fund under ICBC Credit Suisse Asset Management has increased its holdings by 1.2508 million shares, totaling 2.9001 million shares, which represents 3.75% of the circulating shares [2] - The fund, ICBC Credit Suisse Frontier Medical Stock A (001717), has a current scale of 9.33 billion CNY and has achieved a year-to-date return of 41.51%, ranking 537 out of 4222 in its category [2] - The fund manager, Zhao Bei, has a tenure of nearly 11 years, with the fund's best return during this period being 275.3% and the worst being -24.35% [2]

Core Points - The company announced a cash dividend of CNY 0.23000 per share for the 2025 semi-annual profit distribution [2][4] - The total cash dividend distribution amounts to CNY 26,116,213.42 (including tax) based on a total share capital of 113,548,754 shares [4][10] - The profit distribution plan was approved at the annual general meeting held on May 9, 2025 [2] Distribution Plan - The cash dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, after the market closes on the registration date [3][4] - Shareholders who have completed designated transactions can receive their cash dividends at their designated securities business department on the distribution date [4][6] - For shareholders who have not completed designated transactions, the dividends will be held by the China Securities Depository and Clearing Corporation until the designated transaction is completed [4] Taxation Details - For individual shareholders and securities investment funds holding shares for over one year, the cash dividend is exempt from personal income tax, resulting in an actual distribution of CNY 0.23000 per share [7][8] - For shares held for less than one year, the company will not withhold personal income tax at the time of distribution; tax will be calculated and withheld upon the transfer of shares [7][8] - The actual cash dividend for shares held for less than one month is subject to a 20% tax rate, resulting in a net distribution of CNY 0.18400 per share [8][9] Additional Information - The company will not withhold corporate income tax for other corporate shareholders; they are responsible for self-reporting and paying taxes on their cash dividends [10] - For qualified foreign institutional investors (QFII), a 10% corporate income tax will be withheld, resulting in a net cash dividend of CNY 0.20700 per share [9]

Group 1 - The company announced a profit distribution plan for the first half of 2025, proposing a cash dividend of 0.23 yuan per share (tax included) [2] - The record date for the dividend is set for September 12, 2025, with the ex-dividend date and payment date both on September 15, 2025 [2]

重要内容提示： 证券代码：688293 证券简称：奥浦迈 公告编号：2025-083 上海奥浦迈生物科技股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 每股现金红利0.23000元 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/9/12 | 2025/9/15 | 2025/9/15 | 一、通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 9 日的2024年年度股东大会审议通过。 二、分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3、分配方案： 本次利润分配以方案实施前的公司总股本113,548,754股为基数，向全体股东 是否涉及差异化分红送转：否 每股分配比例 1、发放年度：2025年半年度 2、分派对象： 相关日期 3、扣税说明 每股派发现金红利0.23000元（含税）， ...

优化，成就与众不同 Optimization Makes Differences 证券代码：688293 证券简称：奥浦迈 | 2025 年第二次临时股东大会会议须知 3 | | | --- | --- | | 2025 年第二次临时股东大会会议议程 6 | | | 议案 8 | 1： | | 《关于续聘公司会计师事务所的议案》 8 | | 上海奥浦迈生物科技股份有限公司 2025 年第二次临时股东大会 会议资料 二〇二五年九月 1 优化，成就与众不同 Optimization Makes Differences 上海奥浦迈生物科技股份有限公司 2025 年第二次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股东会规则》以及《上海奥浦迈生物科技股份有限公司章程》《上海奥浦 迈生物科技股份有限公司股东大会议事规则》等相关规定，上海奥浦迈生物科技 股份有限公司（以下简称"公司"或"奥浦迈"）特制定本次股东大会会议须知： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作 人员 ...

Core Viewpoint - The biopharmaceutical sector experienced a significant increase of 3.06% on September 5, with Sanofi leading the gains [1] Group 1: Market Performance - The Shanghai Composite Index closed at 3812.51, up 1.24% [1] - The Shenzhen Component Index closed at 12590.56, up 3.89% [1] Group 2: Individual Stock Performance - Sanofi (688336) closed at 61.60, with a rise of 11.80% and a trading volume of 165,400 shares, totaling a transaction value of 9.62 billion [1] - Changchun High-tech (000661) closed at 128.00, increasing by 7.53% with a trading volume of 270,100 shares [1] - Junshi Biosciences (688180) closed at 48.00, up 7.38% with a trading volume of 252,900 shares, totaling 1.17 billion [1] - Tibet Pharmaceutical (600211) closed at 50.48, rising by 7.13% with a trading volume of 220,200 shares, totaling 1.08 billion [1] - Other notable stocks include: - Rongan Bio (688331) at 92.17, up 4.32% [1] - Kexing Pharmaceutical (688136) at 42.27, up 4.14% [1] Group 3: Capital Flow - The biopharmaceutical sector saw a net inflow of 231 million from institutional investors, while retail investors experienced a net outflow of 25.77 million [1]

Core Viewpoint - The company is facing internal dissent regarding its proposed acquisition of 100% equity in Chengli Bio, with independent director Tao Hua'an expressing concerns about the necessity of the merger at this stage [1][2][3]. Group 1: Acquisition Proposal - The company plans to acquire 100% equity of Chengli Bio for a total transaction price of 1.4505 billion yuan, with 710 million yuan to be paid in cash [3]. - The acquisition aims to enhance the company's client resources in preclinical research and expand its customer base for cell culture products and CDMO services [4]. - Tao Hua'an has consistently voted against or abstained from the acquisition proposals, arguing that the company does not currently require such a merger [2][5]. Group 2: Financial Performance - The company's net profit for 2024 was reported at 21.0523 million yuan, a decrease of 61.04% year-on-year, while the net profit after deducting non-recurring gains and losses was 6.5859 million yuan, down 81.03% year-on-year [4]. - The company has faced significant losses in its CDMO business, with a 40.80% year-on-year decrease in operating profit [4]. - The company reported a substantial impairment loss of 9.5369 million yuan for its CDMO asset group, marking a 2176% increase year-on-year [6]. Group 3: Market Conditions - The CRO business of Chengli Bio is facing intense competition domestically, and there are uncertainties in its overseas operations [5]. - The global CDMO industry has entered a downturn since 2023, leading to a reassessment of the company's investment strategies and a reduction in planned capacity [6].

Group 1 - The company held its 13th meeting of the second board on September 2, 2025, where all 7 directors attended, confirming the legality and validity of the meeting [2][4] - The board approved the adjustment of the fundraising plan for the acquisition, reducing the total amount to 362.05 million yuan, with cash payment and fees adjusted accordingly [2][5] - The board confirmed that the adjustments do not constitute a major change to the transaction plan, as there are no changes to the target assets or transaction parties [5][20] Group 2 - The company’s supervisory board also convened on September 2, 2025, with all 3 supervisors present, and unanimously approved the same adjustments made by the board [13][16] - The independent financial advisor confirmed that the adjustments do not constitute a major change according to relevant regulations [22] - The company plans to acquire 100% equity of Pengli Bio-pharmaceutical Technology (Shanghai) Co., Ltd. through a combination of share issuance and cash payment [19][24]